Cambridge Healthtech Institute Announces Featured Presentations at Cancer Biologics 2012

PRLog (Press Release) - Jan. 18, 2012 - NEEDHAM, MASS. – Cambridge Healthtech Institute presents Cancer Biologics 2012, a 3-day event based on in-depth research with experts in the field, being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco. This year we continue to showcase pioneering Cancer Biologics organizations with presentations and case studies from:

BMS  • Pfizer • FDA •  Genentech •  Micromet  • Abbott •  Seattle Genetics  • MedImmune  • ImmunoGen •  Takeda San Francisco •  CovX •  MacroGenics •  Ambrx •  Stanford University •  ImmunGene •  Oxford Biotherapeutics •  Genmab •   Immunocore •  Adaptimmune • Symphogen • Aveo  • Almac Discovery • Biovest

Hear dedicated sessions on:

•   Advances with Multi-Specific Antibodies
•   Developments with Antibody Drug Conjugates
•   Translational Studies for Progression to Clinical
•   Matching the Technology to the Target
•   Biomarkers for Patient Selection
•   Enhanced Effector Function and PKPD
•   Combination Therapies
•   Immunotherapy and Adoptive T Cell Therapy

Featured Presentations:

Antibody-Drug Conjugates: An Emerging Modality for the Targeted Therapy of Liquid and Solid Tumors
Puja Sapra, Ph.D., Director, Bioconjugates, Oncology Research Unit, Pfizer Biotherapeutics

Translational Studies for Progression of ADCs from Discovery to Clinical
Robert Lutz, Ph.D., VP, Translational R&D, ImmunoGen, Inc.

Treatment of Relapsed/Refractory ALL with Bispecific BiTE Antibody Blinatumomab
Patrick A. Baeuerle, Ph.D., CSO, Senior Vice President, R&D, Micromet, Inc.

Elotuzumab, a Humanized Antibody to CS1 for the Treatment of Relapsed/Refractory Multiple Myeloma: Phase 2 Study Results
Anil Singhal, Ph.D., Site Clinical Development Head, Global Pharmaceutical Research & Development, Abbott Biotherapeutics Corp.

PD-1/PD-L1 Blockade
Alan Korman, Ph.D., Vice President, Discovery Research, Bristol-Myers Squibb

The Cancer Biologics conference is one of the program offerings at CHI’s flagship event, the Molecular Medicine Tri-Conference (February 19-23).  This international event features 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs around 4 scientific channels: diagnostics, drug discovery & development, informatics, and cancer. Over 3000 attendees and 150+ sponsors & exhibitors will gather in shared networking functions and in the exhibit/poster hall.

Advance registration discounts are available until January 20, 2012. To view the entire conference agenda and to register, please visit http://www.TriConference.com/Cancer-Biologics

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.